Z Contains A Cyclopentyl Or Cyclopentene Ring Patents (Class 514/530)
  • Patent number: 10703706
    Abstract: The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: July 7, 2020
    Assignee: Corsair Pharma, Inc.
    Inventors: Xiaoming Zhang, Meenakshi S. Venkatraman, Cyrus K. Becker
  • Patent number: 10688072
    Abstract: The present invention relates to a solid pharmaceutical formulation comprising misoprostol or a pharmaceutically acceptable salt thereof. In particular, the invention relates to a dispersible tablet comprising misoprostol or a pharmaceutically acceptable salt thereof, providing alternative routes of administration. The tablet is particularly suited for cervical ripening, induction of labor, prevention and/or treatment of postpartum or post-abortion hemorrhage.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: June 23, 2020
    Assignee: Azanta Danmark A/S
    Inventors: Selvaraj Sekar, Elumalai Baskar, Arunachalam Malaiarasan, Venugopal Prabhakaran
  • Patent number: 10654788
    Abstract: The present invention relates to compounds of formula (I): in which R1 is a hydrogen atom, a phenyl radical, or a straight or branched, saturated or unsaturated hydrocarbon radical having 1 to 8 carbon atoms.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: May 19, 2020
    Assignee: L'OREAL
    Inventors: Maria Dalko, Xavier Marat, Julien Hitce, Chao-Jun Li
  • Patent number: 10464877
    Abstract: The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: November 5, 2019
    Assignee: Corsair Pharma, Inc.
    Inventors: Xiaoming Zhang, Meenakshi S. Venkatraman, Cyrus K. Becker
  • Patent number: 10273206
    Abstract: The present invention provides tromethamine salt of (Z)-7-[3,5-Dihydroxy-2-((E)-3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid in crystalline Form 1 and amorphous form. This compound is may also be referred to as “tromethamine salt of bimatoprost acid.” The invention crystalline form is useful for solid ocular implant or topical formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: April 30, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Thomas K. Karami, Scott W. Smith, Fiona Dubas-Fisher, Adrian St. Clair Brown
  • Patent number: 10210955
    Abstract: A computer implemented method of diagnosing whether a human subject is infected with Zika virus, includes: determining a correlation between a fundus test image of an eye of the human subject for presence of gross macular pigment mottling with a known set of Zika virus infected fundus images and with a known set of healthy fundus images, wherein a high correlation/low correlation between the fundus test image and the known set of Zika virus infected fundus images indicates that there is a high probability/low probability that the human subject is infected with Zika virus, wherein a high correlation/low correlation between the fundus test image and the known set of healthy fundus images indicates that there is a low probability/high probability that the human subject is infected with Zika virus.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: February 19, 2019
    Assignee: ARSH BANERJEE
    Inventor: Arsh Banerjee
  • Patent number: 10150724
    Abstract: Described is a method of synthesizing 6-(5-ethoxyhept-1-yl)bicyclo[3.3.0] octan-3-one by reacting 3-(5-ethoxyhept-1-yl) cyclopentene with dichloroketene. The resulting reaction products are reacted with acetic acid and zinc to produce 4-(5-ethoxyhept-1-yl)bicyclo[3.2.0]heptan-6-one and 4-(5-ethoxyhept-1-yl)bicyclo [3.2.0]heptan-7-one, which are reacted with trimethylsulfonium iodide to produce 2-(5-ethoxyhept-1-yl)spiro[bicyclo[3.2.0]heptane-6,2?-oxirane] and 4-(5-ethoxyhept-1-yl)spiro-[bicyclo-[3.2.0]heptane-6,2?-oxirane]. Lithium iodide is reacted with 2-(5-ethoxyhept-1-yl)spiro[bicyclo[3.2.0]heptane-6,2?-oxirane] and 4-(5-ethoxyhept-1-yl)spiro-[bicyclo-[ 3.2.0]heptane-6,2?-oxirane] to produce 6-(5-ethoxyhept-1-yl)bicyclo[3.3.0]octan-3-one. A method of synthesizing 6-(5-methoxyhept-1-yl)bicyclo[3.3.0]octan-3-one is also described.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: December 11, 2018
    Assignee: Grey Pacific Labs, LLC
    Inventors: Jimmy van Wiltenburg, Rene La Crois
  • Patent number: 10098853
    Abstract: Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular, the chalcone compound bound with 2-hydroxyl in ring A and 4?-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPAR? inducer, p44/42 MAPK inhibitor and cell cycle blocker and does not show toxicity to human aortic smooth muscle cells (HASMCs). In addition, the chalcone compound exhibits synergistic effect with the PPAR? ligand (rosiglitazone) to inhibit cell proliferation and the upregulation of cyclin D1, cyclin D3, interleukin-1? (IL-1?) and interleukin-6 (IL-6) induced by oxidized low density lipoprotein (Ox-LDL).
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: October 16, 2018
    Assignee: Kaohsiung Medical University
    Inventors: Yang-Chang Wu, Fang-Rong Chang, Tusty-Jiuan Hsieh, Suh-Hang Juo, An-Shen Lin, Ying-Chi Du
  • Patent number: 10016441
    Abstract: Prostaglandin conjugates and derivatives and methods for their use to treat glaucoma and/or lower intraocular pressure are disclosed. Additionally, ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma and elevated intraocular pressure are disclosed. Such compositions comprise an effective amount of prostaglandin conjugates or derivatives of the present invention.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: July 10, 2018
    Assignee: NOVARTIS AG
    Inventors: David Archer Ellis, Lukas Scheibler, Najam A. Sharif
  • Patent number: 9962393
    Abstract: In a multilamellar liposome, a pharmaceutical agent is encapsulated in the liposome in the absence of a partition enhancing buffer. Preferably, the pharmaceutical agent is prostaglandin E1 (PGE1). The pharmaceutical agent may be administered to a mammal in an amount effective to treat vascular disease. The release of the pharmaceutical agent from the multilamellar liposome may be regulated by proper selection of liposome size, dosage of the pharmaceutical agent, lipid to pharmaceutical agent weight ratio, and rate of infusion of the pharmaceutical agent.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: May 8, 2018
    Inventor: David P Summers
  • Patent number: 9957220
    Abstract: The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: May 1, 2018
    Assignee: CORSAIR PHARMA, INC.
    Inventors: Xiaoming Zhang, Meenakshi S. Venkatraman, Cyrus K. Becker
  • Patent number: 9872864
    Abstract: The present invention relates to sustained release compositions of prostacyclin, as well as uses thereof, in particular for the prevention and/or treatment of pulmonary arterial hypertension.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: January 23, 2018
    Assignee: Ascendis Pharma A/S
    Inventors: Kennett Sprogøe, Harald Rau, Ulrich Hersel, Thomas Wegge, Oliver Keil, Joachim Zettler
  • Patent number: 9814659
    Abstract: Provided are methods of lightening skin by applying certain aromatic compounds or botanical extracts containing such compounds to the skin.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: November 14, 2017
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Chong Jin Loy, Khalid Mahmood, Claude Saliou, Paul Warren Reddell, Victoria Anne Gordon
  • Patent number: 9770431
    Abstract: The present invention relates to tiglien-3-one compounds and their use in methods of treating or preventing protozoal infections, bacterial infections, parasitic infections and cell proliferative disorders. The tiglien-3-one compounds are also used in methods of controlling pests in humans, animals, plants and the environment.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: September 26, 2017
    Assignee: QBiotics Limited
    Inventors: Paul Warren Reddell, Victoria Anne Gordon
  • Patent number: 9744237
    Abstract: Methods and systems are described for a rapid and sustainable change in the pigment melanin content of melanocytes of the iris stroma, thereby to change the color of the eye. Also described are compositions for lightening or darkening the pigmented tissues or treating a pigmented tissue disease.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: August 29, 2017
    Inventor: Kambiz Thomas Moazed
  • Patent number: 9675570
    Abstract: The present disclosure provides solid compositions comprising a stabilized salt of aminocarboxylic acid. Pharmaceutical compositions comprising [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid monobenzenesulfonate in combination with appropriate additives are also provided.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: June 13, 2017
    Assignee: DAIICHI SANKY COMPANY, LIMITED
    Inventors: Shinichiro Tajiri, Masami Takemura, Shinji Yoshinaga
  • Patent number: 9643911
    Abstract: The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: May 9, 2017
    Assignee: CORSAIR PHARMA, INC.
    Inventors: Xiaoming Zhang, Meenakshi S. Venkatraman, Cyrus K. Becker
  • Patent number: 9623031
    Abstract: Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: ?12-prostaglandin J3 or a derivative thereof, or a prostaglandin D receptor (DP) agonist. The compositions may further include a second anti-cancer drug. ?12-prostaglandin J3 is a stable metabolite of omega-3 fatty acid, eicosapentaenoic acid (EPA), and was discovered to have anti-leukemic properties. ?12-prostaglandin J3 was shown to be highly effective in eradicating the leukemia stem cells (LSC) in two murine models of leukemia, thus increasing the survival of the mice. DP agonists were shown to induce apoptosis of human primary Acute Myelogenous Leukemia cells and may be used in compositions, kits and methods for treating leukemia in a subject. The compositions, kits and methods may be particularly useful for treating human subjects who are resistant to one or more anti-cancer drugs.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: April 18, 2017
    Assignee: THE PENN STATE RESEARCH FOUNDATION
    Inventors: Kumble Sandeep Prabhu, Robert Frank Paulson, Shailaja Hegde, Naveen Kaushal, Ujjawal Hitendra Gandhi
  • Patent number: 9504695
    Abstract: Provided are methods, compositions, systems, and kits for treating metabolic syndrome or a disorder associated with metabolic syndrome, e.g., obesity, dyslipidemia, and/or a diabetic condition, comprising administering systemically to a subject one or more compounds of the Formula (I) and/or (II): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein , L, R1, R2, Z, X, A and B are defined herein.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: November 29, 2016
    Assignee: Topokine Therapeutics, Inc.
    Inventor: Murat V. Kalayoglu
  • Patent number: 9394227
    Abstract: The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: July 19, 2016
    Assignee: CORSAIR PHARMA, INC.
    Inventors: Xiaoming Zhang, Meenakshi S. Venkatraman, Cyrus K. Becker
  • Patent number: 9364455
    Abstract: A combination of compounds is described for the treatment and/or prevention of skin conditions linked to hypopigmentation. Also described, is a combination product that includes at least one prostaglandin receptor agonist and at least one MC1R receptor agonist, as a medicament for use simultaneously, separately or spread out over time for the treatment and/or prevention of skin conditions linked to hypopigmentation, such as vitiligo.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: June 14, 2016
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Philippe Martel, Itaru Suzuki, Johannes Voegel, Philippe Andres, Sandrine Rethore
  • Patent number: 9289435
    Abstract: Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: ?12-prostaglandin J3 or a derivative thereof, or a prostaglandin D receptor (DP) agonist. The compositions may further include a second anti-cancer drug. ?12-prostaglandin J3 is a stable metabolite of omega-3 fatty acid, eicosapentaenoic acid (EPA), and was discovered to have anti-leukemic properties. ?12-prostaglandin J3 was shown to be highly effective in eradicating the leukemia stem cells (LSC) in two murine models of leukemia, thus increasing the survival of the mice. DP agonists were shown to induce apoptosis of human primary Acute Myelogenous Leukemia cells and may be used in compositions, kits and methods for treating leukemia in a subject. The compositions, kits and methods may be particularly useful for treating human subjects who are resistant to one or more anti-cancer drugs.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: March 22, 2016
    Assignee: THE PENN STATE RESEARCH FOUNDATION
    Inventors: Kumble Sandeep Prabhu, Robert Frank Paulson, Shailaja Hegde, Naveen Kaushal, Ujjawal Hitendra Gandhi
  • Patent number: 9265744
    Abstract: Fulvic acid as the active ingredient is used in the treatment or inhibition of multi-drug resistant bacteria, in particular NDM-1 bacteria producing carbapenemase or extended-spectrum ?-lactamase (ES8L) resistant bacteria. The multi-drug resistant bacteria may be gram negative bacteria including, but not limited to, Klebsiella pneumoniae or Escherichia coli. The fulvic acid can be provided in combination with one or more antibiotics from the class of carbapenems or polymyxin antibiotics.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: February 23, 2016
    Assignee: NATRACINE UK LIMITED
    Inventors: Stephen William Leivers, Peter Warn
  • Patent number: 9242950
    Abstract: A method for manufacturing a fatty acid derivative represented by formula (I) is provided: wherein Z1 is wherein R3 is a protecting group for a hydroxy group; which includes the step of reacting a compound of formula (II): wherein Z2 is the same as Z1 except for when Z1 is Z2 is with a co-oxidizer under the presence of an azaadamantane-N-oxyl derivative.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: January 26, 2016
    Assignees: R-TECH UENO, LTD., SUCAMPO AG
    Inventors: Tatsuya Matsukawa, Noriyuki Yamamoto, Ryuji Ueno, Hiroyuki Kotajima, Shunsuke Fukuya, Michiharu Handa, Katsuya Sakata
  • Patent number: 9138438
    Abstract: A method of protecting a retinal neuronal cell by administering an effective amount of a prostaglandin F2? derivative to a patient. A method of preventing or treating an eye disease associated with retinal neuronal cell damage by administering a therapeutically effective amount of a prostaglandin F2? derivative to a patient.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: September 22, 2015
    Assignees: ASAHI GLASS COMPANY, LIMITED, SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Naruhiro Ishida, Atsushi Shimazaki
  • Patent number: 9120738
    Abstract: The invention provides new crystalline forms of 7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid. This compound is commonly referred to as “bimatoprost acid.” The novel crystalline forms are designated forms I, II, and III. The invention crystalline forms are useful for solid ocular implant formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension. In addition, invention crystalline forms are useful for solid or semisolid dosage formulations used to treat ocular hypertension.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: September 1, 2015
    Assignee: Allergan, Inc.
    Inventors: Ke Wu, Shaoxin Feng, Thomas K. Karami, Scott W. Smith
  • Patent number: 9089480
    Abstract: A colloidal anionic oil-in-water emulsion includes a prostaglandin, an oil having a iodine value ?2, a surfactant and water, provided the anionic oil-in-water emulsion does not contain polyvinyl alcohol. The use of the anionic oil-in-water emulsions for enhancing the stability of the prostaglandins, for the treatment of ocular hypertension and/or glaucoma, for promoting growth of eyelashes and/or for treating eyelash hypotrichosis is also described.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: July 28, 2015
    Assignee: SANTEN SAS
    Inventors: Frederic Lallemand, Betty Phillips, Jean-Sebastien Garrigue
  • Patent number: 9089720
    Abstract: The present invention provides a new pharmaceutical application of a 15,15-difluoroprostaglandin F2? derivative. As a result of intensive studies in order to find a new pharmaceutical application of a 15,15-difluoroprostaglandin F2? derivative, it was found that, in a European Phase III clinical trial for tafluprost, one of the 15,15-difluoroprostaglandin F2? derivatives, with patients with open-angle glaucoma or ocular hypertension, tafluprost has actions of growing eyelashes, making eyelashes thicker, and changing the color thereof, that is, has an effect of promoting the growth of hair (eyelashes). Therefore, a 15,15-difluoroprostaglandin F2? derivative is useful as a hair growth promoting agent, and is expected to be useful as an active ingredient of a preventive or therapeutic agent for a disease associated with hair such as alopecia and a hair care product or a hair cosmetic product for regrowing hair, growing hair, increasing hair density, nourishing hair, or the like.
    Type: Grant
    Filed: September 4, 2009
    Date of Patent: July 28, 2015
    Assignees: SANTEN PHARMACEUTICAL CO., LTD., ASAHI GLASS COMPANY, LIMITED
    Inventor: Auli Ropo
  • Patent number: 9072750
    Abstract: The invention relates to a composition for use in treating corneal and conjunctival lesions, wherein the composition comprises a prostaglandin F2alpha or analogue, in a therapeutic amount, said composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative; the invention also relates to a method for treating surface ocular conditions in a patient in need thereof, comprising administering a composition of the invention.
    Type: Grant
    Filed: November 19, 2010
    Date of Patent: July 7, 2015
    Assignee: SANTEN SAS
    Inventors: Jean-Sébastien Garrigue, Frédéric Lallemand, Philippe Daull, Christophe Baudouin
  • Patent number: 9050262
    Abstract: The present invention is directed to compositions and methods for enhancing the health of nails and cuticles in a mammal, including humans. The compositions may be administered topically to the nail bed, nail matrix and cuticle in an amount effective to enhance nail health. The composition is also effective in strengthening and growing nails.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: June 9, 2015
    Assignee: Allergan, Inc.
    Inventor: John G. Walt
  • Publication number: 20150140110
    Abstract: The disclosure describes nanocarried and/or microcarried jasmonate compounds and their pharmaceutical compositions, as well as use thereof for treating or preventing angiogenesis-related or NF-?B-related disorders. Also disclosed are methods of making the nanocarried and/or microcarried compounds and their compositions.
    Type: Application
    Filed: October 27, 2014
    Publication date: May 21, 2015
    Inventor: José E. Fehr Pereira Lopes
  • Publication number: 20150133540
    Abstract: Control or repellency of mosquitoes is accomplished by bringing the insects into contact with at least one of the compounds of the structure (I) wherein R is selected from —OH, ?O, —OC(O)R4, —OR6, —(OR6)2, wherein each R6 is independently selected from an alkyl group containing from 1 to 4 carbon atoms and R4 is a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; X is O or CH2, with the proviso that when X is O R can only be ?O; each Z is independently selected from (CH) and (CH2); y is a numeral selected from 1 and 2; R1 is selected from H or a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to two double bonds and from 1 to 15 carbon atoms; R2 is selected from H and a branched or straight chain, saturated or unsaturated hydrocarbyl group with zero to three double bonds and from 1 to 15 carbon atoms; R3 is selected from the group consisting of H and a branched or straight chain, satur
    Type: Application
    Filed: April 30, 2013
    Publication date: May 14, 2015
    Inventor: Robert H. Bedoukian
  • Publication number: 20150132358
    Abstract: A method and apparatus for administering an active agent such as a medicine to a subject, uses an ocular implant such as a punctal plug, to which the active agent has been applied. The implant is installed at the eye of the subject for administering the active agent via tissues of the eye.
    Type: Application
    Filed: August 29, 2014
    Publication date: May 14, 2015
    Inventors: Steven A. Odrich, Liane C. Glazer
  • Publication number: 20150133546
    Abstract: The lacrimal implant delivery systems and methods described herein provide for controlled release of a therapeutic agent for the treatment of disease, including the treatment of glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agents. Treatment of disease, including glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agent in conjunction with penetration enhancer, such as benzalkonium chloride, and/or artificial tears is also provided.
    Type: Application
    Filed: January 17, 2015
    Publication date: May 14, 2015
    Inventors: Zuhal Butuner, Deepank Utkhede, Sylie Sim, David J. Wiseman
  • Publication number: 20150105462
    Abstract: Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid ester (e.g., isopropyl myristate), optionally comprising an ointment base such as a hydrocarbon base (e.g., petroleum jelly) and/or an organic alcohol (e.g., propylene glycol), that, when topically applied to the skin, locally delivers a therapeutically effective amount of the PFPRA compound to subcutaneous fat under the skin, and methods of preparation. The therapeutic effect is, for example, reduction of the subcutaneous fat under the skin. Further provided are methods of reducing body fat in a subject comprising topically administering the composition to the subject.
    Type: Application
    Filed: December 18, 2014
    Publication date: April 16, 2015
    Applicant: Topokine Therapeutics, Inc.
    Inventors: Michael S. Singer, Murat V. Kalayoglu
  • Publication number: 20150099720
    Abstract: Provided herein are compounds having a structure selected from among Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V) and Formula (VI) that are androgen receptor modulators and/or androgen receptor binding agents. Also disclosed are methods of making and using such compounds, including, but not limited to, using such compounds for treating various conditions.
    Type: Application
    Filed: October 20, 2014
    Publication date: April 9, 2015
    Inventors: Lin Zhi, Robert I. Higuchi, E. Adam Kallel, Cornelis Arjan Van Oeveren, Jyun-Hung Chen, Daniel A. Ruppar, Bijan Pedram, Thomas Lot Stevens Lau, Todd A. Miller
  • Publication number: 20150099805
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Application
    Filed: December 15, 2014
    Publication date: April 9, 2015
    Inventor: Patrick M. Hughes
  • Publication number: 20150079035
    Abstract: The present invention provides, inter alia, a compound having the structure: (Formula (I). Also provided are compositions containing a pharmaceutically acceptable carrier and a compound according to the present invention. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, and methods for treating or ameliorating the effects of a neurodegenerative disease.
    Type: Application
    Filed: April 2, 2013
    Publication date: March 19, 2015
    Inventors: Brent R. Stockwell, Scott J. Dixon, Rachid Skouta
  • Publication number: 20150080430
    Abstract: The present invention relates to methods of treating benign hyperproliferative diseases of the epidermis by administering a composition comprising at least one jasmonate ester derivative. In particular, the present invention provides jasmonate ester derivatives as potent compounds useful for the treatment of disorders such as actinic keratoses with reduced side effects.
    Type: Application
    Filed: September 25, 2014
    Publication date: March 19, 2015
    Applicant: SEPAL PHARMA LTD.
    Inventors: Max HERZBERG, Frederic REVAH
  • Patent number: 8980948
    Abstract: Travoprost medicament compositions for non-daily topical application are useful for simulating or inducing the growth and/or decreasing the loss and/or increasing the density and/or reducing the heterogeneity in the diameter of human hair shafts/follicles, e.g., for the treatment of androgenic alopecia, such medicament compositions being at least twice applied over a time interval of greater than 24 hours.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: March 17, 2015
    Assignee: Galderma Research & Development
    Inventors: Sandrine Rethore, Carine Rosignoli, André Jomard, Johannes Voegel
  • Publication number: 20150073005
    Abstract: To provide a composition for hair growth (hair growth agent) which has high hair growing effects and can be used for prevention or treatment of alopecia. The composition for hair growth comprises as an active ingredient at least one member selected from the group consisting of a compound represented by the formula (1) and a salt thereof. In the formula, R is a carboxy group or an alkoxycarbonyl group.
    Type: Application
    Filed: November 17, 2014
    Publication date: March 12, 2015
    Applicants: ASAHI GLASS COMPANY, LIMITED, SANTEN PHARMACEUTICAL, CO., LTD.
    Inventors: Atsushi Shimazaki, Arata Yasuda, Yasushi Matsumura
  • Publication number: 20150064230
    Abstract: The lacrimal implant delivery systems and methods described herein provide for controlled release of a therapeutic agent for the treatment of disease, including the treatment of glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agents. Treatment of disease, including glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agent in conjunction with penetration enhancer, such as benzalkonium chloride, and/or artificial tears is also provided.
    Type: Application
    Filed: August 25, 2014
    Publication date: March 5, 2015
    Inventors: Zuhal Butuner, Deepank Utkhede, Sylie Sim, David J. Wiseman
  • Publication number: 20150051276
    Abstract: Compounds are used as agents that deter feeding of crops by agricultural pests such as hemiptera, lepidoptera and coleoptera, including, but not limited to, stink bugs, codling moth larvae and granary weevils.
    Type: Application
    Filed: April 30, 2013
    Publication date: February 19, 2015
    Inventor: Robert H. Bedoukian
  • Publication number: 20150037377
    Abstract: The present invention relates to substituted cellulose acetates and methods of use thereof. One embodiment of the present invention provides a coating having a substituted cellulose acetate having a polar substituent that has an oxygen atom covalently bonded to a nonmetal selected from the group of sulfur, phosphorus, and boron; wherein the nonmetal is present in at least about 0.01% by weight of the substituted cellulose acetate.
    Type: Application
    Filed: October 16, 2014
    Publication date: February 5, 2015
    Applicant: Celanese Acetate LLC
    Inventors: Michael T. Combs, Thomas S. Garrett
  • Publication number: 20150025077
    Abstract: This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.
    Type: Application
    Filed: February 27, 2013
    Publication date: January 22, 2015
    Applicant: COYOTE PHARMACEUTICALS, INC.
    Inventors: Hiroaki Serizawa, Ankush B. Argade, Akash Datwani, Natalie Spencer, Yonghua Pan, Florian Ermini
  • Publication number: 20150025020
    Abstract: The present invention relates to a self-preserved oil dispersion. Especially, the present invention relates to a self-preserved oil dispersion including a dispersed oil phase, an aqueous phase and at least one surfactant, wherein said oil dispersion comprises boric acid in an amount ranging from 0.005% to 0.075% in weight of the total weight of the oil dispersion, said amount of boric acid being a preservative effective amount so that the oil dispersion has a preservative activity.
    Type: Application
    Filed: February 22, 2013
    Publication date: January 22, 2015
    Inventors: Jean-Sébastien Garrigue, Frédéric Lallemand, Betty Philips
  • Publication number: 20150018400
    Abstract: Disclosed herein is a method comprising administering a compound to a mammal suffering from an inflammatory bowel disease for the treatment of said disease, said compound having a structure according to Formula I wherein X, Y, B, R2, R3, R4, R5, R6 and n have the meanings found herein.
    Type: Application
    Filed: May 2, 2014
    Publication date: January 15, 2015
    Inventors: YARIV DONDE, JEREMIAH H. NGUYEN, KAREN M. KEDZIE, DANIEL W. GIL, JOHN E. DONELLO, WHA-BIN IM
  • Patent number: 8932567
    Abstract: Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include bimatoprost and minoxidil in a vehicle for topical application to the skin of a mammal, e.g. a human, whereby the combination of bimatoprost and minoxidil produces a faster onset of hair growth in humans or other mammals and wherein said composition brings about a synergestic result of faster onset of hair growth as compared to compositions comprising bimatoprost and minoxidil, alone.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: January 13, 2015
    Assignee: Allergan, Inc.
    Inventors: David F. Woodward, Jenny W. Wang
  • Patent number: 8933120
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: January 13, 2015
    Assignee: Allergan, Inc.
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
  • Publication number: 20150005260
    Abstract: The present invention relates to methods and kits for detecting diastolic dysfunction in subjects without clinical signs of heart failure.
    Type: Application
    Filed: January 2, 2013
    Publication date: January 1, 2015
    Inventors: Faiez Zannad, Patrick Rossignol